Reaction
Cataract Nuclear reporting signals
As of the last recalculation, Cataract Nuclear appears in 649 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is RANIBIZUMAB (PRR 149.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ranibizumab | 104 | 149.4 | 150.0 |
| Faricimab | 8 | 32.0 | 32.1 |
| Dorzolamide Hydrochloride And Timolol Maleate | 6 | 24.6 | 24.6 |
| Timolol | 9 | 24.2 | 24.2 |
| Carboxymethylcellulose Sodium | 7 | 24.1 | 24.2 |
| Bevacizumab | 81 | 23.8 | 23.8 |
| Prednisolone Acetate | 7 | 21.9 | 21.9 |
| Aflibercept | 19 | 20.1 | 20.1 |
| Asfotase Alfa | 6 | 19.4 | 19.4 |
| Brinzolamide | 5 | 18.6 | 18.6 |
| Brimonidine Tartrate | 9 | 16.4 | 16.4 |
| Lifitegrast | 4 | 7.9 | 7.9 |